Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine
Information source: Wyeth
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: HCV-796 (Drug); Desipramine (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Wyeth Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth
Summary
To evaluate the potential pharmacokinetic (PK) interaction of multiple oral doses of HCV-796
and a single dose of desipramine when coadministered to healthy subjects.
Clinical Details
Official title: An Open-Label, Single-Dose Desipramine, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine
Study design: Other, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Pharmacokinetics Study
Primary outcome: Pharmacokinetic (PK)
Secondary outcome: Safety
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy as determined by the investigator on the basis of medical history, physical
examination, clinical laboratory test results, vital signs, and 12-lead ECG.
Locations and Contacts
Philadelphia, Pennsylvania 19148, United States
Additional Information
Starting date: June 2007
Ending date: August 2007
Last updated: April 10, 2008
|
